Information Provided By:
Fly News Breaks for July 21, 2017
INSY
Jul 21, 2017 | 09:34 EDT
Janney Capital analyst Ken Trbovich noted that the FDA's Paragraph IV certifications list earlier this week showed that Insys had received an ANDA filing for Subsys on May 22, which he views as "somewhat negative," but also "not unexpected." While the ANDA raises the possibility of a generic sooner rather than later, Trbovich sees no risk for a generic Subsys until 2020 at the earliest and thinks the company's patents could prevent generic entry until as late as 2030. He keeps a Buy rating and $16 fair value estimate on Insys shares.
News For INSY From the Last 2 Days
There are no results for your query INSY
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.